High Expression of MORC2 is Associated with Poor Clinical Outcomes and Immune Infiltrates in Colon Adenocarcinoma

Purpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated. Methods: The cli...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of general medicine Vol. 16; pp. 4595 - 4615
Main Authors Zhao, Peizhuang, Ning, Jiajia, Huang, Jun, Wei, Binqian, Wang, Zhen, Huang, Xue
Format Journal Article
LanguageEnglish
Published Dove Medical Press Limited 31.10.2023
Dove
Dove Medical Press
Subjects
Online AccessGet full text
ISSN1178-7074
1178-7074
DOI10.2147/IJGM.S420715

Cover

Loading…
Abstract Purpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated. Methods: The clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan--Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3). Results: MORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on. Conclusion: The findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients. Keywords: MORC2, colon adenocarcinoma, diagnosis, prognosis, immune cell infiltration, biomarker
AbstractList Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated.PurposeMicrorchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated.The clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan-Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3).MethodsThe clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan-Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3).MORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on.ResultsMORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on.The findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients.ConclusionThe findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients.
Purpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated. Methods: The clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan--Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3). Results: MORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on. Conclusion: The findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients. Keywords: MORC2, colon adenocarcinoma, diagnosis, prognosis, immune cell infiltration, biomarker
Peizhuang Zhao,* Jiajia Ning,* Jun Huang,* Binqian Wei, Zhen Wang, Xue Huang Department of Geriatrics and Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xue Huang, Department of Geriatrics and Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530000, People’s Republic of China, Email hb960305@163.comPurpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies. However, its prognostic value and immunological role of MORC2 in colon adenocarcinoma (COAD) have never been illustrated.Methods: The clinical parameters and MORC2 expression datasets of COAD patients were obtained from The Cancer Genome Atlas (TCGA). Cancer and adjacent tissue specimens from surgically resected COAD patients were collected, and quantitative real-time PCR was used to detect MORC2 expression. Differentially expressed genes related to MORC2 were discovered and used for functional enrichment analysis. The diagnostic and prognostic values of MORC2 in COAD were conducted using receiver operating characteristics (ROC), Kaplan–Meier survival curve analysis, PrognoScan, Gene Expression Profiling Interactive Analysis (GEPIA) public databases and nomograms. Eventually, the association of MORC2 with tumor microenvironment was analyzed by using TIMER and GSVA package of R (v3.6.3).Results: MORC2 expression was upregulated in COAD tissues, and the RT-qPCR results further verified the reliability of our differential analysis at the transcriptional level. Additionally, higher expression of MORC2 was correlated to a poor prognosis for COAD patients. MORC2 was an independent prognostic factor for COAD and could be a diagnostic factor for early COAD. Furthermore, MORC2 expression was positively correlated with immune cells such as NK cells, TFH cells and so on.Conclusion: The findings demonstrated that overexpression of MORC2 was correlated with worse prognosis and immune infiltrates of COAD. MORC2 can serve as a reliable diagnostic and prognostic biomarker and a target of immunotherapy for COAD patients.Keywords: MORC2, colon adenocarcinoma, diagnosis, prognosis, immune cell infiltration, biomarker
Audience Academic
Author Wei, Binqian
Zhao, Peizhuang
Huang, Xue
Ning, Jiajia
Huang, Jun
Wang, Zhen
Author_xml – sequence: 1
  givenname: Peizhuang
  surname: Zhao
  fullname: Zhao, Peizhuang
– sequence: 2
  givenname: Jiajia
  surname: Ning
  fullname: Ning, Jiajia
– sequence: 3
  givenname: Jun
  surname: Huang
  fullname: Huang, Jun
– sequence: 4
  givenname: Binqian
  surname: Wei
  fullname: Wei, Binqian
– sequence: 5
  givenname: Zhen
  surname: Wang
  fullname: Wang, Zhen
– sequence: 6
  givenname: Xue
  orcidid: 0000-0002-3034-1848
  surname: Huang
  fullname: Huang, Xue
BookMark eNptkktrGzEUhYeSQhO3u_4AQaF0Ebt6jEbjVTFDmrgkuPSxFporja2gkRxppo9_X01tSlyCFhLSuR_n6p6L4swHb4riNcELSkrxfv3p-m7xtaRYEP6sOCdE1HOBRXn26PyiuEjpHuOqqgg7Lx5u7HaHrn7to0nJBo9Ch-42XxqKbEKrlAJYNRiNftphhz6HEFHjrLegHNqMA4TeJKS8Ruu-H71Ba99ZN8RckpD1qAkuI1fa-AAqgvWhVy-L551yybw67rPi-8erb83N_HZzvW5Wt3MoeTXMGWggYCqsWqIJVEaTJQeBgQvCGMOUC8o6wrjuAJuy4rWgAnfatLpUXJRsVqwPXB3UvdxH26v4WwZl5d-LELdSxcGCM7JlbYfrlmoFulxCV-eD4KpaMsqJwjyzPhxY-7HtjQbjc4_uBHr64u1ObsMPSTAXguafnhXvjoQYHkaTBtnbBMY55U0Yk6S1qAWhmE_G3xykW5W9Wd-FjIRJLldCMFZjJiZLiydUeWnTW8i5yIMwpwVvHxXsjHLDLgU3Dnnq6VR4eRBCDClF0_3rk2A55UxOOZPHnGU5_U8OdlATNRuy7umiP59f1x4
CitedBy_id crossref_primary_10_1097_MD_0000000000039299
crossref_primary_10_1007_s12032_024_02464_9
crossref_primary_10_1016_j_mocell_2024_100166
Cites_doi 10.18632/oncotarget.3185
10.1016/j.tranon.2021.101174
10.18632/aging.102003
10.1093/mutage/ger067
10.1159/000495673
10.1016/j.gene.2012.02.011
10.4161/epi.24976
10.3390/antiox8050112
10.1038/s41418-021-00901-0
10.1093/jnci/djz093
10.1186/s13148-019-0642-0
10.1038/sj.bjc.6602589
10.1016/s1470-2045(07)70246-2
10.3748/wjg.v13.i28.3784
10.1016/j.bbamcr.2013.11.012
10.3389/fpls.2017.01720
10.1093/annonc/mdl035
10.1371/journal.pone.0028222
10.1111/cas.13863
10.1136/gut.2004.044214
10.3390/ijms18030567
10.3390/ijms21155311
10.1016/j.ajhg.2020.06.013
10.1038/s41418-018-0259-4
10.1016/j.humpath.2018.03.011
10.1016/s0140-6736(18)30789-x
10.18632/oncotarget.18556
10.1038/s41575-019-0189-8
10.1016/j.celrep.2012.11.018
10.1155/2018/2397863
10.18632/oncotarget.3889
10.1007/s12551-021-00812-x
10.1016/j.canlet.2013.11.011
10.1111/ene.13360
10.1002/humu.10175
10.3748/wjg.v24.i22
10.1016/j.critrevonc.2019.01.023
10.1002/ar.21119
10.3892/ijo.2018.4333
10.1016/j.mam.2019.06.002
10.1016/j.intimp.2020.107041
10.1016/j.bbadis.2018.01.011
10.1038/s41418-018-0095-6
10.1093/bib/bbaa047
10.1038/pj.2016.37
10.1158/0008-5472.CAN-17-1394
10.1093/brain/awv311
10.1093/nar/gkq006
10.1038/bjc.2014.429
10.3748/wjg.v20.i22.6786
10.3390/jcm10112391
10.1016/j.tibs.2003.09.003
ContentType Journal Article
Copyright COPYRIGHT 2023 Dove Medical Press Limited
2023 Zhao et al.
2023 Zhao et al. 2023 Zhao et al.
Copyright_xml – notice: COPYRIGHT 2023 Dove Medical Press Limited
– notice: 2023 Zhao et al.
– notice: 2023 Zhao et al. 2023 Zhao et al.
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.2147/IJGM.S420715
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ: Directory of Open Access Journal (DOAJ)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Zhao et al
EISSN 1178-7074
EndPage 4615
ExternalDocumentID oai_doaj_org_article_b3bf08b2dacd49cf8dac75a693251a05
PMC10577261
A773380375
10_2147_IJGM_S420715
GrantInformation_xml – fundername: ;
GroupedDBID ---
0YH
29J
2WC
53G
5GY
5VS
7X7
8FI
8FJ
8G5
AAYXX
ABUWG
ACGFO
ADBBV
ADRAZ
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C1A
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HMCUK
HYE
IAO
IHR
IHW
IPNFZ
ITC
KQ8
M2O
M48
MK0
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TDBHL
TR2
UKHRP
VDV
PMFND
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c456t-3cdc1ce60ab1d1c6ed195c70c571333025723f135dfc0e46587270fdebd4a5743
IEDL.DBID M48
ISSN 1178-7074
IngestDate Wed Aug 27 01:11:07 EDT 2025
Thu Aug 21 18:35:46 EDT 2025
Fri Jul 11 05:31:39 EDT 2025
Tue Jun 17 22:21:29 EDT 2025
Tue Jun 10 21:13:27 EDT 2025
Thu May 22 21:11:47 EDT 2025
Thu Apr 24 23:04:50 EDT 2025
Tue Jul 01 01:04:40 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License https://creativecommons.org/licenses/by-nc/3.0
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c456t-3cdc1ce60ab1d1c6ed195c70c571333025723f135dfc0e46587270fdebd4a5743
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work
ORCID 0000-0002-3034-1848
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/IJGM.S420715
PQID 2878712054
PQPubID 23479
PageCount 21
ParticipantIDs doaj_primary_oai_doaj_org_article_b3bf08b2dacd49cf8dac75a693251a05
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10577261
proquest_miscellaneous_2878712054
gale_infotracmisc_A773380375
gale_infotracacademiconefile_A773380375
gale_healthsolutions_A773380375
crossref_primary_10_2147_IJGM_S420715
crossref_citationtrail_10_2147_IJGM_S420715
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20231031
PublicationDateYYYYMMDD 2023-10-31
PublicationDate_xml – month: 10
  year: 2023
  text: 20231031
  day: 31
PublicationDecade 2020
PublicationTitle International journal of general medicine
PublicationYear 2023
Publisher Dove Medical Press Limited
Dove
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Dove
– name: Dove Medical Press
References Giuliani (ref40) 2019; 8
Li (ref7) 2013; 8
Naccarati (ref44) 2012; 27
Marcuello (ref19) 2019; 69
Manning (ref8) 2003; 28
Pagès (ref53) 2018; 391
Guillen Sacoto (ref42) 2020; 107
Wang (ref23) 2010; 293
Zhang (ref12) 2015; 6
Sevilla (ref26) 2016; 139
Worthley (ref45) 2007; 13
Pan (ref24) 2018; 53
Xi (ref1) 2021; 14
Liu (ref43) 2022
Buccafusca (ref3) 2019; 136
Liao (ref33) 2019; 11
Ciccolallo (ref38) 2005; 54
Tong (ref32) 2018; 1864
Liu (ref36) 2019; 110
Sun (ref50) 2020; 8
Ando (ref41) 2017; 24
Franke (ref6) 2019; 111
Wang (ref35) 2018; 25
Li (ref9) 2012; 2
Lukaszewicz-Zajac (ref15) 2021; 10
Keum (ref5) 2019; 16
Koch (ref25) 2017; 8
Sanchez-Solana (ref29) 2014; 1843
Zhang (ref27) 2018; 78
Binefa (ref37) 2014; 20
Liu (ref30) 2019; 26
Pellino (ref18) 2018; 2018
Iacopetta (ref49) 2006; 17
Tuupanen (ref13) 2014; 111
Jin (ref21) 2020; 89
Iacopetta (ref48) 2003; 21
Mármol (ref4) 2017; 18
Wang (ref11) 2015; 6
Villéger (ref2) 2018; 24
Zhang (ref17) 2014; 345
Kim (ref52) 2016; 48
Chen (ref14) 2011; 6
Zhou (ref51) 2021; 22
Ding (ref10) 2018; 76
Shao (ref22) 2010; 38
Liao (ref28) 2017; 8
Verdecchia (ref39) 2007; 8
Guddeti (ref31) 2021; 13
Liu (ref34) 2018; 51
Han (ref16) 2019; 11
Lopez (ref47) 2012; 499
Ogunwobi (ref20) 2020; 21
Smith (ref46) 2005; 92
References_xml – volume: 6
  start-page: 9877
  year: 2015
  ident: ref11
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3185
– volume: 14
  start-page: 101174
  year: 2021
  ident: ref1
  publication-title: Transl Oncol
  doi: 10.1016/j.tranon.2021.101174
– volume: 11
  start-page: 3639
  year: 2019
  ident: ref33
  publication-title: Aging
  doi: 10.18632/aging.102003
– volume: 27
  start-page: 211
  year: 2012
  ident: ref44
  publication-title: Mutagenesis
  doi: 10.1093/mutage/ger067
– volume: 51
  start-page: 1679
  year: 2018
  ident: ref34
  publication-title: Cell Physiol Biochem
  doi: 10.1159/000495673
– volume: 499
  start-page: 81
  year: 2012
  ident: ref47
  publication-title: Gene
  doi: 10.1016/j.gene.2012.02.011
– volume: 8
  start-page: 685
  year: 2013
  ident: ref7
  publication-title: Epigenetics
  doi: 10.4161/epi.24976
– volume: 8
  start-page: 79
  year: 2019
  ident: ref40
  publication-title: Antioxidants
  doi: 10.3390/antiox8050112
– year: 2022
  ident: ref43
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-021-00901-0
– volume: 111
  start-page: 1131
  year: 2019
  ident: ref6
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djz093
– volume: 11
  start-page: 51
  year: 2019
  ident: ref16
  publication-title: Clin Epigenetics
  doi: 10.1186/s13148-019-0642-0
– volume: 92
  start-page: 1813
  year: 2005
  ident: ref46
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6602589
– volume: 8
  start-page: 784
  year: 2007
  ident: ref39
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(07)70246-2
– volume: 8
  start-page: 34
  year: 2020
  ident: ref50
  publication-title: J Immunother Cancer
– volume: 13
  start-page: 3784
  year: 2007
  ident: ref45
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v13.i28.3784
– volume: 1843
  start-page: 316
  year: 2014
  ident: ref29
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbamcr.2013.11.012
– volume: 8
  start-page: 1720
  year: 2017
  ident: ref25
  publication-title: Front Plant Sci
  doi: 10.3389/fpls.2017.01720
– volume: 17
  start-page: 842
  year: 2006
  ident: ref49
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdl035
– volume: 6
  start-page: e28222
  year: 2011
  ident: ref14
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0028222
– volume: 110
  start-page: 135
  year: 2019
  ident: ref36
  publication-title: Cancer Sci
  doi: 10.1111/cas.13863
– volume: 54
  start-page: 268
  year: 2005
  ident: ref38
  publication-title: Gut
  doi: 10.1136/gut.2004.044214
– volume: 18
  start-page: 567
  year: 2017
  ident: ref4
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms18030567
– volume: 21
  year: 2020
  ident: ref20
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21155311
– volume: 107
  start-page: 352
  year: 2020
  ident: ref42
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2020.06.013
– volume: 26
  start-page: 1905
  year: 2019
  ident: ref30
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-018-0259-4
– volume: 76
  start-page: 58
  year: 2018
  ident: ref10
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2018.03.011
– volume: 391
  start-page: 2128
  year: 2018
  ident: ref53
  publication-title: Lancet
  doi: 10.1016/s0140-6736(18)30789-x
– volume: 8
  start-page: 97941
  year: 2017
  ident: ref28
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.18556
– volume: 16
  start-page: 713
  year: 2019
  ident: ref5
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-019-0189-8
– volume: 2
  start-page: 1657
  year: 2012
  ident: ref9
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2012.11.018
– volume: 2018
  start-page: 2397863
  year: 2018
  ident: ref18
  publication-title: Gastroenterol Res Pract
  doi: 10.1155/2018/2397863
– volume: 6
  start-page: 16461
  year: 2015
  ident: ref12
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3889
– volume: 13
  start-page: 507
  year: 2021
  ident: ref31
  publication-title: Biophys Rev
  doi: 10.1007/s12551-021-00812-x
– volume: 345
  start-page: 17
  year: 2014
  ident: ref17
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2013.11.011
– volume: 24
  start-page: 1274
  year: 2017
  ident: ref41
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13360
– volume: 21
  start-page: 271
  year: 2003
  ident: ref48
  publication-title: Hum Mutat
  doi: 10.1002/humu.10175
– volume: 24
  start-page: 2327
  year: 2018
  ident: ref2
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v24.i22
– volume: 136
  start-page: 20
  year: 2019
  ident: ref3
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2019.01.023
– volume: 293
  start-page: 1002
  year: 2010
  ident: ref23
  publication-title: Anat Rec
  doi: 10.1002/ar.21119
– volume: 53
  start-page: 59
  year: 2018
  ident: ref24
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2018.4333
– volume: 69
  start-page: 107
  year: 2019
  ident: ref19
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2019.06.002
– volume: 89
  start-page: 107041
  year: 2020
  ident: ref21
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2020.107041
– volume: 1864
  start-page: 1104
  year: 2018
  ident: ref32
  publication-title: Biochim Biophys Acta Mol Basis Dis
  doi: 10.1016/j.bbadis.2018.01.011
– volume: 25
  start-page: 2086
  year: 2018
  ident: ref35
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-018-0095-6
– volume: 22
  year: 2021
  ident: ref51
  publication-title: Brief Bioinform
  doi: 10.1093/bib/bbaa047
– volume: 48
  start-page: 829
  year: 2016
  ident: ref52
  publication-title: Polymer Journal
  doi: 10.1038/pj.2016.37
– volume: 78
  start-page: 5780
  year: 2018
  ident: ref27
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-17-1394
– volume: 139
  start-page: 62
  year: 2016
  ident: ref26
  publication-title: Brain
  doi: 10.1093/brain/awv311
– volume: 38
  start-page: 2813
  year: 2010
  ident: ref22
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkq006
– volume: 111
  start-page: 1657
  year: 2014
  ident: ref13
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2014.429
– volume: 20
  start-page: 6786
  year: 2014
  ident: ref37
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v20.i22.6786
– volume: 10
  start-page: 567
  year: 2021
  ident: ref15
  publication-title: J Clin Med
  doi: 10.3390/jcm10112391
– volume: 28
  start-page: 573
  year: 2003
  ident: ref8
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2003.09.003
SSID ssj0066613
Score 2.3095524
Snippet Purpose: Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many...
Microrchidia 2 (MORC2) is a universally expressed molecule that has recently been identified as a chromatin modulator and elevated in many malignancies....
Peizhuang Zhao,* Jiajia Ning,* Jun Huang,* Binqian Wei, Zhen Wang, Xue Huang Department of Geriatrics and Gastroenterology, the First Affiliated Hospital of...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 4595
SubjectTerms Adenocarcinoma
B cells
biomarker
Cancer
Cancer patients
Chromatin
colon adenocarcinoma
Colon cancer
Development and progression
diagnosis
Gene expression
Genes
Genetic aspects
Genomes
Genomics
immune cell infiltration
Immunotherapy
Killer cells
morc2
Original Research
Patient outcomes
Prognosis
SummonAdditionalLinks – databaseName: DOAJ: Directory of Open Access Journal (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yB_Eirg9sXTWC4kHaTdLv4zjsurMwrqgLewt54sCYducB_nyrOplhWxEv3ppOQadTVamvuitfEfLKM123Bvu7tNrnZce7vK28zxXrWOdqzyPFxvxjfXZZnl9VVzdafWFNWKQHjgt3rAvtWauFVcaWnfEtXDSVqgF3VFxF9lKIebtkKu7BgMl5EcvcsQ_P8ez8w_zdl1JAPK1GAWjg6f9zN_69QvJGyDm9R-4mrEgncY6H5JYL98ntefob_oBcY5EGPfmZalkD7T2dX3yeCrpY0926O0vxWyv91PcrmlhAl_RiuwFTc2uqgqUzPCPi6Cz4xXIgq13TRaBT2BYDncC-BOFuBU_sv6uH5PL05Ov0LE8tFHIDyGiTF8YablzNlOaWm9pZ3lWmYabC5LQAwNOIwvOist4wVwIcATzDvHXalqoCdPGIHIQ-uMeEtloJWwtflxoc37Gu8a1qvPC2cM51KiNvd-sqTeIXxzYXSwl5BmpBohZk0kJGXu-lf0Rejb_IvUcV7WWQDXu4ATYik43If9lIRl6ggmU8Wrr3aTlpGsjQsQtwRt4MEujVMGmj0uEEeHXkxxpJHo0kwRvNaPjlzogkDmEJW3D9di0hNYXkVABEzkg7sq7Ry41HwuLbQPmN3ZgbSHaf_I_leEruCIBqMQIfkYPNauueAbTa6OeDF_0CgsckBQ
  priority: 102
  providerName: Directory of Open Access Journals
Title High Expression of MORC2 is Associated with Poor Clinical Outcomes and Immune Infiltrates in Colon Adenocarcinoma
URI https://www.proquest.com/docview/2878712054
https://pubmed.ncbi.nlm.nih.gov/PMC10577261
https://doaj.org/article/b3bf08b2dacd49cf8dac75a693251a05
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZ2kRAviKsojGIkEA8ow87NyQNCXdVtnZRtGlTqW-TrqFQclrTS-PccJ25FGEi8VFV92iY5Pj7fSY6_D6G3hog0k07fJRMmiHOaB1liTMBJTnKdGtpRbBTn6eksPpsn8x20URv1F7D5a2nn9KRm9fLw9ubnZwj4T66Nmcbs4_TspDj8EoeQLZNdtA85iTkRhyLePk8AjN4KJVMKNRODrNm1wN_5di85tRz-d1fqP7snf0tHxw_RA48j8ahz_CO0o-1jdK_wT8qfoBvXwIEnt77P1eLK4OLiahziRYM3PtEKu_uw-LKqauwZQpf4Yr2CaagbzK3CU7d_ROOpNYtlS2Tb4IXFY1gyLR7BmgWpsIZ_rL7zp2h2PPk6Pg28vEIgATWtgkgqSaVOCRdUUZlqRfNEMiITV7hGAIZYGBkaJcpIomOAKoB1iFFaqJgngDyeoT1bWf0c4UzwUKWhSWMBi4ImOTMZZyY0KtJa53yAPmyuayk997iTwFiWUIM4L5TOC6X3wgC921r_6Dg3_mF35Fy0tXFM2e0HVX1d-sArRSQMyUSouFRxLk0Gb1jCU8CtCeUEfuS1c3DZbTvdxns5Ygyqd6cQPEDvWws3B-GgJfcbF-DUHXdWz_KgZwmRKnvDbzaTqHRDrr3N6mrdlFC2QuEaAnweoKw3u3on1x-xi28tHbhTamZQCL_47-N8ie6HgNW6FHyA9lb1Wr8CbLUSQ7TL5myI9o8m55dXw_YOBbyezOmwDahfrkInAA
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High+Expression+of+MORC2+is+Associated+with+Poor+Clinical+Outcomes+and+Immune+Infiltrates+in+Colon+Adenocarcinoma&rft.jtitle=International+journal+of+general+medicine&rft.au=Zhao%2C+Peizhuang&rft.au=Ning%2C+Jiajia&rft.au=Huang%2C+Jun&rft.au=Wei%2C+Binqian&rft.date=2023-10-31&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-7074&rft.eissn=1178-7074&rft.volume=16&rft.spage=4595&rft_id=info:doi/10.2147%2FIJGM.S420715&rft.externalDocID=A773380375
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-7074&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-7074&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-7074&client=summon